Does Amerigroup Cover Forteo (Teriparatide)?

What Is Forteo and Why Is It Prescribed?

Forteo (teriparatide) is a recombinant fragment of human parathyroid hormone (PTH 1-34) administered as a once-daily 20 mcg subcutaneous injection. The FDA approved Forteo in November 2002 for postmenopausal women, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis who face high fracture risk. [1] Teriparatide works by stimulating osteoblast activity rather than simply slowing bone resorption, making it a true anabolic agent.

Clinical Efficacy Data

The key Fracture Prevention Trial (N=1,637 postmenopausal women) showed teriparatide 20 mcg reduced the risk of new vertebral fractures by 65% and non-vertebral fragility fractures by 53% over a median 19 months of treatment compared with placebo (P<0.001 for both). [2] Lumbar spine bone-mineral density (BMD) increased a mean of 9.7% from baseline at 19 months. [2]

Approved Indications and Lifetime Limit

The FDA label caps teriparatide use at 24 months cumulative lifetime exposure due to osteosarcoma risk observed in rat studies at suprapharmacological doses. [1] This cap directly shapes how Amerigroup writes its prior-authorization (PA) criteria: most PA approvals are granted in 12-month increments up to the 24-month ceiling.

Who Qualifies Clinically

The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines recommend anabolic therapy as first-line treatment for patients with very high fracture risk, defined as T-score at or below -3.0, multiple prior fragility fractures, or a fracture while on antiresorptive therapy. [3] Amerigroup's PA criteria mirror these thresholds closely.

How Amerigroup Medicaid Plans Handle Forteo Coverage

Amerigroup operates Medicaid managed-care contracts in roughly a dozen states, including Texas, Georgia, Virginia, New Jersey, Nevada, and Tennessee. Each state Medicaid agency sets the drug benefit rules, and Amerigroup administers them. This means the specific formulary tier, copay structure, and PA requirements differ by state.

Common Prior Authorization Requirements

Across most Amerigroup Medicaid contracts, a PA request for teriparatide typically must document:

• A DXA T-score of -2.5 or lower at the lumbar spine or hip, or a prior low-trauma fragility fracture
• A documented trial of at least one oral bisphosphonate (alendronate or risedronate) for a minimum of six months unless contraindicated
• Evidence of intolerance or therapeutic failure on bisphosphonate therapy
• Diagnosis confirmed by the prescribing physician, generally an endocrinologist, rheumatologist, or orthopedist

The AACE notes that bisphosphonates remain the standard first-line choice for most patients because of their low cost and long safety record, which explains why step therapy is common in managed-care PA policies. [3]

Step Therapy: The Bisphosphonate Hurdle

Step therapy is the single most common reason Forteo PAs are initially denied by Amerigroup. Generic alendronate costs roughly $10 to $15 per month on most Medicaid formularies, while teriparatide list price approaches $3,500 per month. [4] Medicaid drug-utilization programs are designed to exhaust lower-cost options first.

If a member cannot tolerate bisphosphonates due to esophageal disease, severe renal impairment (eGFR <35 mL/min/1.73 m²), or documented jaw osteonecrosis, the prescriber can request a step-therapy exemption by submitting clinical documentation to Amerigroup's pharmacy benefit manager.

HealthRX Step-Therapy Bypass Framework for Teriparatide PA:

1. Attach the most recent DXA report with T-scores at spine and hip.
2. Include a fracture history summary (date, location, trauma level).
3. Document the specific bisphosphonate tried, the dose, the duration, and the reason for failure or discontinuation.
4. Add the most recent renal function panel if contraindication is eGFR-based.
5. Provide a letter of medical necessity signed by the specialist, citing AACE or NOF guidelines by name.

Amerigroup Medicare Advantage Formulary Coverage

Amerigroup also administers Medicare Advantage plans in several states through its parent company Elevance Health (formerly Anthem). Medicare Advantage Part D formularies are filed annually with CMS and can change each plan year. [5]

Formulary Tier and Cost-Sharing

On most Amerigroup Medicare Advantage Part D formularies, teriparatide (brand Forteo or generic) appears on Tier 4 or Tier 5 (specialty tier). Specialty-tier cost-sharing in 2024 plans commonly ranges from 25% to 33% coinsurance after the deductible. The 2024 Medicare Part D out-of-pocket cap of $8,000 (and $2,000 starting in 2025 under the Inflation Reduction Act) provides a ceiling for catastrophic drug costs. [5]

Coverage Determination Process

Members may request a coverage determination by submitting CMS Form CMS-10146 or by having the prescribing physician submit a PA request directly through Amerigroup's online portal or by fax. Under Medicare rules, Amerigroup must respond to a standard coverage determination within 72 hours or within 24 hours for an expedited request when a standard timeframe could seriously jeopardize health. [6]

Non-Formulary Exception Requests

If teriparatide is not on the current Amerigroup Medicare Advantage formulary, the prescriber may file a formulary exception. CMS requires the plan to grant an exception when the requested drug is medically necessary and all covered alternatives are not clinically appropriate for the specific member. [6] A strong formulary exception letter cites the specific clinical reason each formulary alternative is unsuitable.

Generic Teriparatide: Does It Change Coverage?

Eli Lilly's Forteo patent expired, and the FDA approved the first generic teriparatide (marketed as Bynder by Alvogen) in 2023. [7] Generic teriparatide is therapeutically equivalent to Forteo under the FDA's AB rating. [7] Most Amerigroup formularies have already transitioned to preferring the generic, which lowers list price and may reduce the specialty-tier cost-sharing for covered members.

Prescribers writing "dispense as written" for brand Forteo on Amerigroup plans may face a higher member cost-share or a separate brand-name PA. Switching to generic teriparatide preserves the same clinical efficacy: the FDA's bioequivalence standard requires the same active ingredient, dose, route, and comparable pharmacokinetics. [7]

What Happens If Amerigroup Denies Forteo?

A denial is not final. Federal and state law guarantee the right to appeal, and denial overturn rates improve substantially when appeals include complete clinical documentation.

Level 1 Internal Appeal

The first step is an internal appeal submitted to Amerigroup within the plan-specified timeframe (typically 60 days from denial for Medicaid, 60 days for Medicare Advantage). The appeal should include:

• A new or updated letter of medical necessity
• Copies of DXA results with T-score values labeled
• Office notes documenting fracture history or prior drug failures
• Peer-reviewed citations, such as the Fracture Prevention Trial [2] or AACE guidelines [3]

Level 2 External Appeal and IRO Review

If the internal appeal fails, Medicare Advantage members may escalate to the Qualified Independent Contractor (QIC) review, and Medicaid members may request an independent review organization (IRO) review or a state fair hearing. The National Osteoporosis Foundation states that high-fracture-risk patients who have already fractured while on antiresorptive therapy have a compelling medical case for anabolic therapy. [8]

State Fair Hearing (Medicaid Only)

Medicaid members have the right to a state fair hearing before an administrative law judge. Requesting a fair hearing before the effective date of a reduction or termination preserves the member's right to continued service during the hearing process under federal Medicaid continuation-of-benefits rules. [9]

Alternatives to Forteo That Amerigroup Typically Covers

When teriparatide is denied, several other osteoporosis treatments may be covered at lower cost-sharing tiers.

Bisphosphonates

Oral alendronate (Fosamax generic) is the most consistently covered option across all Amerigroup plans. A 2022 Cochrane review (68 RCTs, N=45,000+) confirmed alendronate reduces vertebral fracture risk by approximately 45% and hip fracture risk by 40% in high-risk postmenopausal women. [10] Risedronate (Actonel generic) and ibandronate (Boniva generic) are also broadly covered.

Denosumab (Prolia)

Denosumab 60 mg subcutaneous every six months is covered under the medical benefit (not pharmacy) for many Amerigroup Medicaid and Medicare Advantage members when billed under the appropriate J-code (J0897). The FREEDOM trial (N=7,808) showed denosumab reduced vertebral fracture risk by 68%, hip fracture risk by 40%, and non-vertebral fracture risk by 20% over 36 months. [11] Importantly, denosumab does not require renal dose adjustment, making it an option when bisphosphonates are contraindicated due to low eGFR.

Abaloparatide (Tymlos)

Abaloparatide is a synthetic PTHrP analogue with a similar anabolic mechanism to teriparatide. The ACTIVE trial (N=2,463) showed abaloparatide 80 mcg/day reduced new vertebral fractures by 86% versus placebo over 18 months (P<0.001). [12] Amerigroup's PA criteria for abaloparatide generally mirror those for teriparatide. If teriparatide is denied, abaloparatide may be an alternative worth requesting, particularly if the prescriber can argue clinical differentiation.

Romosozumab (Evenity)

Romosozumab (Evenity) 210 mg subcutaneous monthly for 12 months is an anti-sclerostin antibody with both anabolic and antiresorptive properties. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% compared with alendronate alone over 24 months. [13] Romosozumab carries an FDA boxed warning for cardiovascular risk and is contraindicated in patients with recent myocardial infarction or stroke. [14] Amerigroup PA criteria typically require the same step-therapy prerequisites as for teriparatide.

Cost Assistance Programs When Coverage Is Denied

If Amerigroup denies coverage and appeals are unsuccessful, three additional pathways exist.

Eli Lilly Insulin Value Program / Lilly Cares

Eli Lilly runs the Lilly Cares Foundation patient assistance program for uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level). Eligible patients may receive Forteo at no cost. [15]

340B Drug Pricing Program

Federally qualified health centers (FQHCs) and other 340B-eligible providers can dispense teriparatide at the 340B ceiling price, which is substantially below wholesale acquisition cost. Patients whose care is managed at an FQHC may access lower net pricing even without complete insurance coverage. [16]

GoodRx and Manufacturer Rebate Cards

Generic teriparatide (Bynder) listed on GoodRx in January 2025 at roughly $1,800 to $2,200 per month at major chain pharmacies, compared with the Forteo brand list price near $3,400. For commercially insured members who lose Amerigroup coverage (for example, during a coverage gap), a manufacturer discount card from Alvogen may apply additional savings.

How to Submit a Forteo PA to Amerigroup: Step-by-Step

Successful PA submissions share specific features. The following sequence applies to most Amerigroup Medicaid and Medicare Advantage plans.

Step 1: Confirm the Correct Form

Amerigroup uses either its internal PA request form or the CoverMyMeds electronic PA platform. The prescriber's office should verify which pathway is active for the specific member's plan ID before submitting.

Step 2: Attach Clinical Documentation

Include the DXA report (dated within 24 months), the most recent office note with fracture history, renal function labs if relevant, and a letter of medical necessity. The letter should state the T-score, the prior therapy tried, the reason for failure, and the clinical guideline basis for anabolic therapy. AACE 2020 guidelines [3] and the National Osteoporosis Foundation 2022 Clinician's Guide [8] are appropriate references.

Step 3: Use the Correct Diagnosis Codes

Primary diagnosis codes for osteoporosis PA requests include M81.0 (age-related osteoporosis without current pathological fracture) and M80.00XA (age-related osteoporosis with current pathological fracture, initial encounter). Pairing the drug request with a relevant ICD-10 code that matches the FDA indication avoids automatic rejections.

Step 4: Track the PA Decision Deadline

For Medicaid, states generally require PA decisions within 3 business days for non-urgent requests and 24 hours for urgent requests. For Medicare Advantage, the 72-hour standard and 24-hour expedited rules apply under CMS regulations. [6] If no decision arrives by the deadline, this constitutes a constructive denial and triggers appeal rights.

Monitoring Requirements During Teriparatide Therapy

Prescribers managing patients on approved teriparatide therapy under Amerigroup coverage should document monitoring visits to maintain PA renewal.

Baseline and Follow-Up DXA

The FDA label recommends assessing BMD at baseline and periodically during treatment. [1] AACE guidelines suggest a follow-up DXA at 12 to 24 months to document response. [3] Amerigroup PA renewals typically ask for evidence of clinical benefit, and a follow-up DXA showing BMD improvement or stability supports renewal approval.

Serum Calcium

Teriparatide may transiently raise serum calcium. The FDA label recommends baseline serum calcium and notes that teriparatide should not be used in patients with pre-existing hypercalcemia. [1] Amerigroup may request calcium results as part of the clinical record during PA renewal.

Sequential Therapy After Teriparatide

When the 24-month teriparatide course ends, antiresorptive therapy must follow to preserve the BMD gains. A study published in the New England Journal of Medicine (Saag et al., VERO trial, N=1,360) found that patients who transitioned to zoledronic acid after teriparatide maintained BMD gains over 24 additional months. [17] Amerigroup will cover the antiresorptive sequencing as standard formulary therapy; this part generally does not require a new specialty PA.

Key Physician and Guideline Quotations

The AACE 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis state: "Patients with very high fracture risk, including those with a recent fracture, those with T-scores of -3.0 or below, and those who fracture while on antiresorptive therapy, should be treated with anabolic agents as initial therapy." [3]

The National Osteoporosis Foundation 2022 Clinician's Guide adds: "Sequential therapy following anabolic treatment with an antiresorptive agent is essential to sustain bone mineral density gains achieved during anabolic therapy." [8]

These direct guideline statements are the strongest clinical foundation for an Amerigroup PA or appeal letter.